知镜 Cognispect · 医学文献与研究工作台

Recent and anticipated novel drug approvals (3Q 2026 through 2Q 2027).

Endriukaitis L, Han J, Tran T, Choi A, Levitsky AM, Rim MH.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026-08-29 · PMID 42667689

文献摘要

Purpose Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by sharing new and anticipated novel drug approvals. Summary Selected drug approvals anticipated in the 12-month period covering the third quarter of 2026 through the second quarter of 2027 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics selected from 66 novel drugs awaiting US Food and Drug Administration (FDA) approval. This year's pipeline features novel therapies for various disease states including rare and inherited genetic disorders, immunology and inflammatory diseases, and continued advancements in both targeted oncology therapies and gene therapies. Conclusion Novel therapies continue to strengthen the current drug pipeline.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。